Lynx Dx has commercially launched MyProstateScore 2.0 (MPS2), a urine test kit for prostate cancer intended for at-home sample collection by patients.

Lynx Dx已经商业推出MyProstateScore 2.0（MPS2），这是一款用于前列腺癌的尿液检测试剂盒，旨在让患者在家自行采集样本。

The test can be ordered by physicians and is now qualified for Medicare reimbursement.

该测试可由医生订购，现在符合医疗保险报销条件。

MPS2 analyses a comprehensive set of 18 gene transcripts to predict the presence of clinically significant prostate cancer.

MPS2分析了18个基因转录本的综合数据集，以预测临床上显著的前列腺癌的存在。

Lynx Dx has developed the algorithm for “optimising” diagnostic accuracy and offering clinical flexibility, enabling the test to be used with or without including clinical risk factors, based on the preference of the physician.

Lynx Dx 开发了“优化”诊断准确性和提供临床灵活性的算法，使测试可以根据医生的偏好选择是否包含临床风险因素。

MPS2 can be used by patients to test either in their own homes or at a medical facility.

MPS2 可供患者在自己家中或医疗机构进行测试。

This flexibility aligns the test with telehealth practices and expands access for individuals in remote or underserved areas. Moreover, the urine samples remain stable without the need for temperature control, stated the company.

这种灵活性使测试与远程医疗实践相一致，并扩大了偏远或服务不足地区个人的使用机会。此外，公司表示，尿液样本在无需温度控制的情况下仍能保持稳定。

According to the company, recent research has demonstrated that MPS2 delivered “high” accuracy in predicting clinically significant prostate cancer risk.

据该公司称，最近的研究表明，MPS2 在预测临床上显著的前列腺癌风险方面提供了“高”准确性。

The study showed that MPS2 “outperformed” traditional prostate-specific antigen (PSA) testing, identifying up to 53% of men who would have an unnecessary biopsy, while keeping 91%–94% sensitivity for detecting high-grade cancer.

研究表明，MPS2“优于”传统的前列腺特异性抗原（PSA）检测，能够识别出高达53%的男性避免不必要的活检，同时保持91%-94%的高分级癌症检测灵敏度。

Lynx Dx chief medical officer Spencer Heaton said: “Giving patients the option to take the test at home, without the need to schedule a visit to the doctor or have a DRE, adds convenience, removes stigma and broadens access to a powerful method of screening for a serious disease.

山猫Dx首席医疗官斯宾塞·希顿表示：“让患者选择在家进行测试，无需预约看医生或进行直肠指检，增加了便利性，消除了羞耻感，并拓宽了对一种严重疾病进行筛查的有效方法的获取途径。"

“MyProstateScore 2.0 offers more clarity about the need for a biopsy in a way that aligns seamlessly with modern clinical workflows.”

“MyProstateScore 2.0 提供了更清晰的活检需求信息，与现代临床工作流程无缝对接。”

Lynx Dx provides diagnostic testing services while leveraging technology from the University of Michigan. The company focuses on developing genomic tests especially where there is a significant need.

Lynx Dx 提供诊断测试服务，同时利用密歇根大学的技术。该公司专注于开发基因组测试，特别是在有重大需求的领域。